サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1434850

抗腫瘍薬市場：適応症別、投与経路別、薬剤クラス別、流通チャネル別、エンドユーザー別-2024～2030年の世界予測

Anti-Tumor Drugs Market by Indications (Breast Cancer, Leukemia, Lung Cancer), Route of Administration (Intra-muscular, Intraperitoneal, Intravenous), Drug Class, Distribution Channels, End User - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 192 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
抗腫瘍薬市場：適応症別、投与経路別、薬剤クラス別、流通チャネル別、エンドユーザー別-2024～2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗腫瘍薬市場規模は2023年に348億9,000万米ドルと推計され、2024年には391億4,000万米ドルに達し、CAGR 12.24%で2030年には783億5,000万米ドルに達すると予測されます。

抗腫瘍薬の世界市場

主な市場の統計
基準年[2023］ 348億9,000万米ドル
予測年[2024] 391億4,000万米ドル
予測年 [2030] 783億5,000万米ドル
CAGR（%） 12.24%
抗腫瘍薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは抗腫瘍薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、抗腫瘍薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-抗腫瘍薬市場の市場規模および予測は？

2-抗腫瘍薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-抗腫瘍薬市場における技術動向と規制の枠組みは？

4-抗腫瘍薬市場における主要ベンダーの市場シェアは？

5-抗腫瘍薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 高齢者人口の急増に伴うがん発生率の増加
      • がんの早期診断と治療に対する意識の高まり
      • 政府によるヘルスケア費の増加
    • 抑制要因
      • 抗がん剤は高額で生存率も低い
    • 機会
      • パイプライン医薬品の入手可能性と腫瘍治療用の個別化医薬品の需要の急増
      • 抗がん治療における最近の技術革新
    • 課題
      • 抗がん剤の使用に伴う好ましくない転帰
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 抗腫瘍薬市場適応症別

  • 乳がん
  • 白血病
  • 肺がん
  • 黒色腫
  • 前立腺がん

第7章 抗腫瘍薬市場：投与経路別

  • 筋肉内
  • 腹腔内
  • 静脈内
  • 脳室内またはくも膜下腔内
  • 小胞内
  • オーラル
  • 皮下
  • 話題

第8章 抗腫瘍薬市場薬剤クラス別

  • 細胞毒性物質
  • ホルモン療法
  • 標的療法
    • モノクローナル抗体
    • 低分子阻害剤

第9章 抗腫瘍薬市場流通チャネル別

  • 病院薬局
  • 小売薬局

第10章 抗腫瘍薬市場：エンドユーザー別

  • クリニック
  • 病院
  • 専門センター

第11章 南北アメリカの抗腫瘍薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第12章 アジア太平洋地域の抗腫瘍薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第13章 欧州・中東・アフリカの抗腫瘍薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第14章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第15章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AbbVie Inc.
    • Amgen inc.
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Cybrexa Therapeutics
    • Dr. Reddy's Laboratories Ltd.
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Genentech, Inc.
    • Getwell Oncology
    • GLS Pharma Pvt. Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Otsuka Pharmaceutical Co., Ltd
    • Pfizer Inc.
    • PharmaMar
    • Sanofi SA
    • Taiho Oncology, Inc
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
  • 主要な製品ポートフォリオ

第16章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTI-TUMOR DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-TUMOR DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTI-TUMOR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTI-TUMOR DRUGS MARKET DYNAMICS
  • FIGURE 7. ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2030 (%)
  • FIGURE 8. ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 12. ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
  • FIGURE 14. ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 16. ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. ANTI-TUMOR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 26. ANTI-TUMOR DRUGS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTI-TUMOR DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTI-TUMOR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-TUMOR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTI-TUMOR DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTI-TUMOR DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTI-TUMOR DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTI-TUMOR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTI-TUMOR DRUGS MARKET SIZE, BY INTRA-MUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENTRICULAR OR INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVESICULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTI-TUMOR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTI-TUMOR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTI-TUMOR DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. ANTI-TUMOR DRUGS MARKET SIZE, BY CYTOTOXICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. ANTI-TUMOR DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 25. ANTI-TUMOR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. ANTI-TUMOR DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 28. ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. ANTI-TUMOR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. ANTI-TUMOR DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. ANTI-TUMOR DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 284. ANTI-TUMOR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 285. ANTI-TUMOR DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 286. ANTI-TUMOR DRUGS MARKET LICENSE & PRICING
目次
Product Code: MRR-710B1F0AC621

[192 Pages Report] The Anti-Tumor Drugs Market size was estimated at USD 34.89 billion in 2023 and expected to reach USD 39.14 billion in 2024, at a CAGR 12.24% to reach USD 78.35 billion by 2030.

Global Anti-Tumor Drugs Market

KEY MARKET STATISTICS
Base Year [2023] USD 34.89 billion
Estimated Year [2024] USD 39.14 billion
Forecast Year [2030] USD 78.35 billion
CAGR (%) 12.24%
Anti-Tumor Drugs Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anti-Tumor Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-Tumor Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anti-Tumor Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Cybrexa Therapeutics, Dr. Reddy's Laboratories Ltd., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Getwell Oncology, GLS Pharma Pvt. Ltd., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., PharmaMar, Sanofi SA, Taiho Oncology, Inc, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Anti-Tumor Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indications
    • Breast Cancer
    • Leukemia
    • Lung Cancer
    • Melanoma
    • Prostate Cancer
  • Route of Administration
    • Intra-muscular
    • Intraperitoneal
    • Intravenous
    • Intraventricular or Intrathecal
    • Intravesicular
    • Oral
    • Subcutaneous
    • Topical
  • Drug Class
    • Cytotoxics
    • Hormonal Therapy
    • Targeted Therapy
      • Monoclonal Antibodies
      • Small Molecule Inhibitors
  • Distribution Channels
    • Hospital Pharmacies
    • Retail Pharmacies
  • End User
    • Clinics
    • Hospitals
    • Specialty Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Anti-Tumor Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-Tumor Drugs Market?

3. What are the technology trends and regulatory frameworks in the Anti-Tumor Drugs Market?

4. What is the market share of the leading vendors in the Anti-Tumor Drugs Market?

5. Which modes and strategic moves are suitable for entering the Anti-Tumor Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Anti-Tumor Drugs Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in incidence of cancer with the surge in the geriatric population
      • 5.1.1.2. Growing awareness regarding early diagnosis and treatment for the cancer
      • 5.1.1.3. Increase in expenditures on healthcare by government
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of anticancer drugs and low survival rate
    • 5.1.3. Opportunities
      • 5.1.3.1. Availability of pipelined drugs and upsurge in demand for personalized medicines for the tumor treatment
      • 5.1.3.2. Recent innovations in anticancer therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Unfavorable outcomes associated with the use of cancer drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Anti-Tumor Drugs Market, by Indications

  • 6.1. Introduction
  • 6.2. Breast Cancer
  • 6.3. Leukemia
  • 6.4. Lung Cancer
  • 6.5. Melanoma
  • 6.6. Prostate Cancer

7. Anti-Tumor Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intra-muscular
  • 7.3. Intraperitoneal
  • 7.4. Intravenous
  • 7.5. Intraventricular or Intrathecal
  • 7.6. Intravesicular
  • 7.7. Oral
  • 7.8. Subcutaneous
  • 7.9. Topical

8. Anti-Tumor Drugs Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Cytotoxics
  • 8.3. Hormonal Therapy
  • 8.4. Targeted Therapy
    • 8.5.1. Monoclonal Antibodies
    • 8.5.2. Small Molecule Inhibitors

9. Anti-Tumor Drugs Market, by Distribution Channels

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Retail Pharmacies

10. Anti-Tumor Drugs Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Hospitals
  • 10.4. Specialty Centers

11. Americas Anti-Tumor Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Anti-Tumor Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Anti-Tumor Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
  • 14.2. Market Share Analysis, By Key Player
  • 14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

  • 15.1. Key Company Profiles
    • 15.1.1. AbbVie Inc.
    • 15.1.2. Amgen inc.
    • 15.1.3. Astellas Pharma Inc.
    • 15.1.4. AstraZeneca PLC
    • 15.1.5. Bayer AG
    • 15.1.6. Biogen Inc.
    • 15.1.7. Bristol-Myers Squibb Company
    • 15.1.8. Celgene Corporation
    • 15.1.9. Cybrexa Therapeutics
    • 15.1.10. Dr. Reddy's Laboratories Ltd.
    • 15.1.11. Eisai Co., Ltd.
    • 15.1.12. Eli Lilly and Company
    • 15.1.13. F. Hoffmann-La Roche Ltd
    • 15.1.14. Genentech, Inc.
    • 15.1.15. Getwell Oncology
    • 15.1.16. GLS Pharma Pvt. Ltd.
    • 15.1.17. Merck & Co., Inc.
    • 15.1.18. Novartis AG
    • 15.1.19. Otsuka Pharmaceutical Co., Ltd
    • 15.1.20. Pfizer Inc.
    • 15.1.21. PharmaMar
    • 15.1.22. Sanofi SA
    • 15.1.23. Taiho Oncology, Inc
    • 15.1.24. Takeda Pharmaceutical Company Limited
    • 15.1.25. Teva Pharmaceutical Industries Ltd.
  • 15.2. Key Product Portfolio

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing